WebMD’s Post

Wegovy—Novo Nordisk, is now the first weight-loss medication to also win FDA approval as an intervention for lowering cardiovascular (CV) risk in adults with obesity or overweight. The findings showed that Wegovy reduced the risk of stroke, heart attack, and other CV problems by 20% in this population. Semaglutide, which is also the active ingredient in Novo's diabetes drug Ozempic, works by delaying emptying of the stomach — which has the effect of suppressed appetite in users. While FDA's decision raises hope that more insurers will cover Wegovy for more patients, effectively bringing production up to meet demand and driving prices down are still challenges. https://lnkd.in/ePvvr8-H

amid the hype around the GLP-1s, with their multibillion-dollar sales and corresponding reputation as a modern miracle of medicine, a sort of pharmaco-amnesia has taken hold across America. Patients and physicians alike have forgotten, if indeed they ever knew, that the agents of the “weight-loss revolution”—Ozempic and Wegovy, Mounjaro and Zepbound—are just the latest medications for obesity. And that older drugs—among them Qsymia, Orlistat, and Contrave—are still available. Indeed, the best of these latter treatments might produce, on average, one-half the benefit you’d get from using GLP-1s in terms of weight loss, at less than one-30th the price. --- A Drug Half as Good as Ozempic for One-30th the Price New obesity drugs are remarkable. But few people realize how useful the old ones can be. By Daniel Engber https://lnkd.in/eNGjkQzm

Today’s FDA-approved #obesity medications are primed to become tomorrow’s novel treatments across multidimensional states of disease – from #diabetes to heart failure. In our latest article, nephrologist and Biorasi SAB member, Jamie P. Dwyer, MD, discusses the concept of #diabesitology and the potential of drugs on the #GLP1 axis >> https://bit.ly/3V6CKDm

STAT reports on Novo Nordisk’s phase 1 trial of experimental oral medicine amycretin, with an average of 13.1% weight loss after 12 weeks. The weight loss is fast and large, in comparison to about 6% at the same time point for injectable medication Wegovy. Amycretin targets well-known GLP-1 as well as amylin – a hormone from the pancreas that reduces food intake by delayed stomach emptying, and well as decreasing blood glucose levels. A Phase II trial of the drug will commence in the second half of 2024, with results due in early 2026. https://lnkd.in/eGmjgnZq

FDA Grants Approval for Resistant Hypertension Management to Idorsia’s Tryvio The FDA has approved Idorsia Ltd's drug Tryvio for the treatment of resistant hypertension in adults. Tryvio is an endothelin receptor antagonist that targets the endothelin pathway to regulate blood pressure. This approval provides clinicians with a new tool to address the challenges of uncontrolled blood pressure. Idorsia specifically developed Tryvio to address the needs of patients who do not respond to multiple antihypertensive medications. Hypertension is a major contributor to cardiovascular disease, affecting a significant portion of the global population. Until now, there were no FDA-approved systemic antihypertensive therapies targeting the endothelin pathway. The FDA approval was based on data from the Phase III PRECISION trial, which demonstrated the efficacy of Tryvio in reducing blood pressure. Tryvio's approval marks the first oral antihypertensive agent in over three decades to target a new therapeutic pathway. For more details please click the link! https://lnkd.in/daW6bGRp #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

🎉 Exciting news in healthcare: Merck's new drug Winrevair shows promise for treating pulmonary hypertension. 💊 Winrevair offers hope for improved treatment outcomes. 🌟 Read more about this groundbreaking advancement in the article below. https://lnkd.in/gTYp6RPM #HealthcareInnovation #PulmonaryHypertension #Merck

Will be interesting to see next phase results

Check out this white paper on patient-centric measures for GLP-1 interventions.

More data on GLP-1 drugs from Blue Health Intelligence. Patients taking these powerful anti-obesity medications should be under the care of an obesity medicine specialist. With only 8,200 board-certified Obesity Medicine Specialists in the US compared to over 975,000 physicians, expertise is key. Including this supervision in your benefits plan is crucial for success. #GLP1s #ozempic #wegovy #zepbound #antiobesitymeds #healthinsurance #employeebenefits #PBMs #Burnhambenefits #thebaldwingroup #BWIN Link to the article: https://lnkd.in/g_zdNNnz

Partners Daiichi Sankyo and Esperion are celebrating approval from the European Commission for expanded labeling of two non-statin drugs to treat hypercholesterolemia and reduce the risk of cardiovascular events by lowering LDL cholesterol. The treatments can be used alone or in combination with statins. An identical label expansion in the US earlier this year increased the treatable population there to about 70 million patients. Up to 80% of European patients are not reaching the recommended guidelines for LDL cholesterol goals. These new treatment options may benefit patients who have not seen improvement on their current medications. https://hubs.la/Q02yk4Bh0 #cardiovasculardisease #cvd #hypercholesterolemia #ldlcholesterol #daiichisankyo #esperion